Polyrizon

About

Funding history · 7 rounds · $32.5M total

Offices

Q&A

When did Polyrizon go public and on what exchange?

Polyrizon went public on NASDAQ in October 2024 with an Initial Public Offering (IPO) of $4.2 million.

What is Polyrizon's primary focus as a biotech company?

Polyrizon is a development-stage biotech company focused on developing innovative medical device hydrogels delivered as nasal sprays, utilizing its proprietary Capture and Contain™ (C&C) and Trap & Target™ (T&T) platforms.

What was the latest public offering amount for Polyrizon?

In May 2025, Polyrizon had a public offering of $47.2 million.

What is the status of Polyrizon's PL-14 Allergy Blocker as of September 2025?

In September 2025, Polyrizon submitted a Pre-Sub Package to the FDA for its PL-14 Allergy Blocker and reported successful intranasal delivery in its latest study.

What recent patent expansion did Polyrizon announce?

In May 2026, Polyrizon announced a U.S. patent expansion for its intranasal drug delivery platform.

What is the status of Polyrizon's NASARIX™ Allergy Blocker clinical trial as of June 2026?

In June 2026, Polyrizon secured three U.S. sites for the NASARIX™ trial and received Central IRB approval for its allergy blocker clinical trial.

What strategic move did Polyrizon announce in March 2026 regarding Colugo?

In March 2026, Polyrizon announced its intention to acquire up to a 20% stake in Colugo, a developer of advanced eVTOL drones.

Team · 10

Tomer Izraeli

Founder · Founder & CEO

Nir Ben Yosef

CFO

Tidhar Turgeman

CRO

Daphna Avital

Chief People Officer

Asaf Itzhaik

Director

Oz Adler

Director

Omer Srugo

Director

Liat Sidi

Director

Yehonatan Zalman Vinokur

Director

Prof. Smadar Cohen

CSO (Chief Scientific Officer)

Sectors & technology

Highlights

Tags